Forte Biosciences, Inc. (FBRX) — Financial statements
Income statement, balance sheet, and cash flow for Forte Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.06↑64.1% | 0.04↑333.3% | 0.01 | 0.00↓100.0% | 0.04 | |
| Gross Profit | -0.06↓64.1% | -0.04↓333.3% | -0.01 | 0.00↑100.0% | -0.04 | |
| Operating Expenses | ||||||
| R&D Expenses | 58↑174.8% | 21↓3.1% | 22↑290.8% | 6↓59.6% | 14 | |
| General & Administrative Expenses | 12 | 0.00↓100.0% | 11↑28.0% | 8↑8.8% | 8 | |
| Selling & Marketing Expenses | 0.00 | 0.00↑100.0% | -0.01 | 0.00 | 0.00 | |
| SG&A Expenses | 12↓19.3% | 15↑44.8% | 11↑27.9% | 8↑8.8% | 8 | |
| Other Expenses | 0.00 | 0.00 | 0.00↓100.0% | 0.02 | 0.00 | |
| Operating Expenses | 71↑93.2% | 37↑12.6% | 32↑133.7% | 14↓35.3% | 21 | |
| Total Costs & Expenses | 71↑93.0% | 37↑12.7% | 32↑133.8% | 14↓35.3% | 21 | |
| Operating Results | ||||||
| Operating Income | -71↓93.0% | -37↓12.7% | -32↓133.8% | -14↑35.3% | -21 | |
| Depreciation & Amortization | 0.06↑64.1% | 0.04↑333.3% | 0.01↓75.0% | 0.04↑0.0% | 0.04 | |
| EBITDA | -71↓99.2% | -35↓9.1% | -32↓134.3% | -14↑35.4% | -21 | |
| EBIT | -71↓99.2% | -35↓9.2% | -32↓133.8% | -14↑35.3% | -21 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↑106.6% | 1↑16.9% | 1 | 0.00 | 0.00 | |
| Interest Income | 3↑106.6% | 1↑16.9% | 1 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -1 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 2↑106.3% | 1↑11.3% | 1↑5841.2% | 0.02↑107.7% | -0.22 | |
| Income Before Tax | -68↓92.6% | -35↓12.7% | -31↓126.8% | -14↑36.1% | -22 | |
| Income Tax Expense | 1 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -69↓95.5% | -35↓12.7% | -31↓126.8% | -14↑36.1% | -22 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -69↓95.5% | -35↓12.7% | -31↓127.1% | -14↑36.1% | -22 | |
| Bottom-Line Net Income | -69↓95.5% | -35↓12.7% | -31↓126.8% | -14↑36.1% | -22 | |
| EPS (Basic) | -4.71↑61.3% | -12.17↑51.2% | -24.92↓24.8% | -19.96↑48.6% | -38.85 | |
| EPS (Diluted) | -4.71↑61.3% | -12.17↑51.2% | -24.92↓24.8% | -19.96↑48.6% | -38.85 | |
| Weighted Average Shares | 147↑4947.4% | 3↑130.9% | 1↑81.6% | 0.70↑24.5% | 0.56 | |
| Weighted Average Diluted Shares | 147↑4947.4% | 3↑130.9% | 1↑81.6% | 0.70↑24.5% | 0.56 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.